Amedeo Smart

Free Medical Literature Service



Ovarian Neoplasms

  Free Subscription

Articles published in
Cancer Lett
    February 2024
  1. LIU J, Liu C, Ma Y, Pan X, et al
    STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs).
    Cancer Lett. 2024 Feb 17:216700. doi: 10.1016/j.canlet.2024.216700.
    >> Share

    November 2023
  2. GARG V, Kumar L
    Metronomic chemotherapy in ovarian cancer.
    Cancer Lett. 2023 Nov 1:216469. doi: 10.1016/j.canlet.2023.216469.
    >> Share

    October 2023
  3. DOGRA S, Elayapillai SP, Qu D, Pitts K, et al
    Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.
    Cancer Lett. 2023 Oct 12:216437. doi: 10.1016/j.canlet.2023.216437.
    >> Share

    September 2023
  4. VENKATA PP, Jayamohan S, He Y, Alejo S, et al
    Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.
    Cancer Lett. 2023 Sep 13:216383. doi: 10.1016/j.canlet.2023.216383.
    >> Share

    August 2023
  5. ZHANG X, Guo H, Chen J, Xu C, et al
    Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
    Cancer Lett. 2023 Aug 17:216355. doi: 10.1016/j.canlet.2023.216355.
    >> Share

    July 2023
  6. CHEN X, Zhou J, Li X, Wang X, et al
    Corrigendum to "Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype" [Cancer Lett. 435 (28 October 2018) 80-91].
    Cancer Lett. 2023 Jul 8:216292. doi: 10.1016/j.canlet.2023.216292.
    >> Share

    May 2023
  7. SHAO Y, Li H, Wu Y, Wang X, et al
    The feedback loop of AURKA/DDX5/TMEM147-AS1/let-7 drives lipophagy to induce cisplatin resistance in epithelial ovarian cancer.
    Cancer Lett. 2023;565:216241.
    >> Share

    April 2023
  8. MOSKOVICH D, Alfandari A, Finkelshtein Y, Weisz A, et al
    Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233].
    Cancer Lett. 2023;563:216196.
    >> Share

    January 2023
  9. ZHANG Y, Qiu JG, Jia XY, Ke Y, et al
    METTL3-mediated N6-methyladenosine modification and HDAC5/YY1 promote IFFO1 downregulation in tumor development and chemo-resistance.
    Cancer Lett. 2023;553:215971.
    >> Share

    Molecular characteristics and clinical behaviour of epithelial ovarian cancers.
    Cancer Lett. 2023;555:216057.
    >> Share

    June 2022
  11. RUSSO A, Zizhao Y, Heyrman GM, Cain BP, et al
    Versican secreted by the ovary links ovulation and migration in fallopian tube derived serous cancer.
    Cancer Lett. 2022 Jun 10:215779. doi: 10.1016/j.canlet.2022.215779.
    >> Share

    May 2022
  12. WANG W, Jo H, Park S, Kim H, et al
    Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer.
    Cancer Lett. 2022 May 12:215735. doi: 10.1016/j.canlet.2022.215735.
    >> Share

    April 2022
  13. ZHAO Z, Shuang T, Gao Y, Lu F, et al
    Targeted delivery of exosomal miR-484 reprograms tumor vasculature for chemotherapy sensitization.
    Cancer Lett. 2022;530:45-58.
    >> Share

    January 2022
  14. SOTO-GAMEZ A, Wang Y, Zhou X, Seras L, et al
    Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist.
    Cancer Lett. 2022;525:67-75.
    >> Share

  15. HERNANDEZ I, Cohen M
    Linking cell-surface GRP78 to cancer: From basic research to clinical value of GRP78 antibodies.
    Cancer Lett. 2022;524:1-14.
    >> Share

    December 2021
  16. QIAO HY, Zhang Q, Wang JM, Jiang JY, et al
    TRIM29 regulates the SETBP1/SET/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer.
    Cancer Lett. 2021;529:85-99.
    >> Share

  17. LIU C, Huang Y, Qin T, You L, et al
    AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway.
    Cancer Lett. 2021 Dec 20. pii: S0304-3835(21)00638.
    >> Share

    November 2021
  18. PIN F, Prideaux M, Huot JR, Essex AL, et al
    Non-bone metastatic cancers promote osteocyte-induced bone destruction.
    Cancer Lett. 2021;520:80-90.
    >> Share

    September 2021
  19. PI R, Yang Y, Hu X, Li H, et al
    Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth.
    Cancer Lett. 2021 Sep 21. pii: S0304-3835(21)00464.
    >> Share

    August 2021
  20. YAMAWAKI K, Mori Y, Sakai H, Kanda Y, et al
    Integrative analyses of gene expression and chemosensitivity of patient-derived ovarian cancer spheroids link G6PD-driven redox metabolism to cisplatin chemoresistance.
    Cancer Lett. 2021;521:29-38.
    >> Share

  21. YOON MJ, Cha H, Ahn J, Lee D, et al
    Dysfunctional activity of classical DNA end-joining renders acquired resistance to carboplatin in human ovarian cancer cells.
    Cancer Lett. 2021;520:267-280.
    >> Share

    February 2021
  22. LUO Q, Wu X, Zhang Y, Shu T, et al
    Corrigendum to 'ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2' [Canc. Lett. 427 (2018) 9-17].
    Cancer Lett. 2021;498:243.
    >> Share

    January 2021
  23. LIU Y, Yang J, Shi Z, Tan X, et al
    In vivo selection of highly metastatic human ovarian cancer sublines reveals role for AMIGO2 in intra-peritoneal metastatic regulation.
    Cancer Lett. 2021 Jan 29. pii: S0304-3835(21)00048.
    >> Share

  24. BHARDWAJ V, Tan YQ, Wu MM, Ma L, et al
    Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives.
    Cancer Lett. 2021 Jan 8. pii: S0304-3835(21)00010.
    >> Share

    December 2020
  25. BUNGSY M, Palmer MCL, Jeusset LM, Neudorf NM, et al
    Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
    Cancer Lett. 2020 Dec 5. pii: S0304-3835(20)30649.
    >> Share

    November 2020
  26. MOSKOVICH D, Alfandari A, Finkelshtein Y, Weisz A, et al
    DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.
    Cancer Lett. 2020 Nov 19. pii: S0304-3835(20)30603.
    >> Share

    June 2020
  27. ZHANG M, Wang Y, Matyunina LV, Akbar A, et al
    The ability of miRNAs to induce mesenchymal-to-epithelial transition (MET) in cancer cells is highly dependent upon genetic background.
    Cancer Lett. 2020;480:15-23.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016